FDA Sets a Late-2026 Decision on Adding a PARP Inhibitor to Hormone Therapy for Advanced Prostate Cancer
FDA granted priority review to talazoparib plus enzalutamide for HRR-altered metastatic prostate cancer. A decision is expected in late 2026.
Medical Daily ·